Article info

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Authors

  1. Correspondence to Professor Lorenzo Antonuzzo; lorenzo.antonuzzo{at}unifi.it
View Full Text

Citation

Gambale E, Fancelli S, Caliman E, et al
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Publication history

  • Accepted December 12, 2021
  • First published January 31, 2022.
Online issue publication 
January 31, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.